AQST - Aquestive Therapeutics, Inc.
| Previous Close | 3.7100 |
| Open | 3.8600 |
| Bid | 3.1000 x 1300 |
| Ask | 3.8700 x 800 |
| Day's Range | 3.6800 - 3.9700 |
| 52 Week Range | 2.9600 - 20.6960 |
| Volume | 81,461 |
| Avg. Volume | 114,351 |
| Market Cap | 94.601M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6050 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.00 |
- Zacks
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -22.39% and 6.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aquestive Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
Reported positive topline data from single dose crossover pharmacokinetic (PK) trial for Libervant™ (diazepam) Buccal Film and expects to complete its rolling New Drug.
- GlobeNewswire
Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study
The study confirms the dosing algorithm developed for Libervant (diazepam) buccal film, a potentially first in class oral treatment for breakthrough or cluster seizuresLibervant.
- Zacks
Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Aquestive Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that management will present at the 2019 Wedbush PacGrow Healthcare Conference to be held in New York, NY on August 13-14. Aquestive will present on Tuesday, August 13th at 9:45 am EDT. Aquestive Therapeutics is a specialty pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients.
- PR Newswire
Aquestive Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Business Highlights on August 7, 2019
WARREN, N.J., July 18, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm® technology to meet patients' unmet needs and solve therapeutic problems, today announced that it will report results for the second quarter ended June 30, 2019 and provide a business update on Wednesday, August 7, 2019 before the market open. The Company will host an investment community conference call at 8:00 a.m. ET on Wednesday, August 7, 2019. There will also be a simultaneous, live webcast available on the Investors section of the Company's website at https://investors.aquestive.com/events-and-presentations.
- Simply Wall St.
What Percentage Of Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Do Insiders Own?
A look at the shareholders of Aquestive Therapeutics, Inc. (NASDAQ:AQST) can tell us which group is most powerful...
- PR Newswire
Aquestive Therapeutics Completes $70 Million Debt Refinancing
WARREN, N.J., July 15, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST) ("Aquestive"), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm® technology to meet patients' unmet needs and solve therapeutic problems, today announced that it has completed a private placement of $70 million of 12.5% Senior Secured Notes due June 2025 and warrants, and refinanced its existing credit facility. The financing, led by Madryn Asset Management, LP ("Madryn"), with participation by other institutional investors, provided net proceeds of approximately $67 million after expenses. The net proceeds of the financing were used by Aquestive to repay all outstanding obligations under the Company's prior credit facility of approximately $52 million.
- PR Newswire
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
WARREN, N.J. , June 7, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' ...
- PR Newswire
Aquestive Therapeutics Completes Enrollment in Libervant™ (diazepam buccal film) Crossover Study
WARREN, N.J., June 4, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company, today announced it has completed enrollment in a single dose crossover pharmacokinetic (PK) trial for Libervant™ (diazepam buccal film), which is in development for the management of select patients with refractory epilepsy who require treatment to control episodes of increased seizure activity, or "seizure clusters." The Company also initiated a rolling New Drug Application (NDA) submission for Libervant in May 2019 with the U.S. Food and Drug Administration (FDA).
- Associated Press
Aquestive Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the Warren, New Jersey-based company said it had a loss of 59 cents. The specialty pharmaceutical company posted revenue of $12.6 million in the period. Aquestive Therapeutics shares ...
- GlobeNewswire
IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil
IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has entered into a definitive worldwide agreement with Aquestive Therapeutics, Inc. (AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, for the co-development and commercialization of Tadalafil oral films (the “Agreement”) for the treatment of erectile dysfunction (“ED”). The companies will jointly undertake further co-development and commercialization of Tadalafil oral film products, and will equally share (50/50) net profits from worldwide product sales.
- PR Newswire
Aquestive Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights
- U.S. launch of Sympazan® (clobazam) Oral Film progressing to plan - Rolling NDA submission for Libervant™ (diazepam) Buccal Film expected to start in second quarter 2019 - Phase 1 Proof of Concept study ...
- PR Newswire
Aquestive Therapeutics Announces Daniel Barber Named to Chief Operating Officer
WARREN, N.J., May 7, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced the appointment of Daniel Barber to the new position of Senior Vice President, Chief Operating Officer (COO) of Aquestive Therapeutics. Mr. Barber has worked at Aquestive since 2007, most recently in the role of Senior Vice President, Chief Strategy and Development Officer. In his expanded role as COO, Mr. Barber will also oversee end-to-end product operations, including product development, manufacturing, and quality assurance.
- Simply Wall St.
Need To Know: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Insiders Have Been Buying Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares...
- PR Newswire
Aquestive Therapeutics to Announce First Quarter 2019 Financial Results and Recent Business Highlights on May 8, 2019
WARREN, N.J., April 17, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that it will report results for the first quarter ended March 31, 2019 and provide a business update on Wednesday, May 8, 2019 before the market open. The Company will host an investment community conference call at 8:00 a.m. ET on Wednesday, May 8, 2019. There will also be a simultaneous, live webcast available on the Investors section of the Company's website at https://investors.aquestive.com/events-and-presentations.
- PR Newswire
Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS
WARREN, N.J., April 16, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for the investigational product riluzole oral film (ROF), which the Company intends to market under the brand name Exservan™. ROF is a novel formulation of riluzole, which is used as an adjunctive therapy in the treatment of amyotrophic lateral sclerosis (ALS). The Company is exploring commercial opportunities for ROF in the U.S. and abroad.
- PR Newswire
Aquestive Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
WARREN, N.J. , March 25, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic ...
- Zacks
Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why
Aquestive Therapeutics (AQST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Associated Press
Aquestive Therapeutics: 4Q Earnings Snapshot
On a per-share basis, the Warren, New Jersey-based company said it had a loss of 56 cents. The specialty pharmaceutical company posted revenue of $16.8 million in the period. For the year, the company ...
- PR Newswire
Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
- Secured U.S. Food and Drug Administration (FDA) approval and launched the first proprietary commercial product in its epilepsy franchise, SYMPAZAN™ (clobazam) Oral Film - Advancing two late stage CNS ...
- PR Newswire
Aquestive Therapeutics to Present at Oppenheimer's 29th Annual Healthcare Conference
WARREN, N.J. , March 7, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic ...
- PR Newswire
Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights on March 14, 2019
WARREN, N.J., Feb. 19, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that it will report results for the fourth quarter and full year ended December 31, 2018 and provide a business update on Thursday, March 14, 2019 before the market open. The Company will host an investment community conference call at 8:00 a.m. ET on Thursday, March 14, 2019. There will also be a simultaneous, live webcast available on the Investors section of the Company's website at https://investors.aquestive.com/events-and-presentations.
- PR Newswire
Aquestive Therapeutics to Present at 2019 BIO CEO & Investor Conference
WARREN, N.J., Feb. 8, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems today announced that management will present at the BIO CEO & Investor Conference to be held in New York, NY on February 11 and 12. Aquestive Therapeutics is a specialty pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. Aquestive is advancing a late-stage proprietary product pipeline to treat CNS conditions and provide alternatives to invasively-administered standard of care therapies.
